CytomX Therapeutics
CTMX
134 hedge funds and large institutions have $315M invested in CytomX Therapeutics in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 47 increasing their positions, 38 reducing their positions, and 15 closing their positions.
113% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 15
24% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 38
15% more funds holding
Funds holding: 117 → 134 (+17)
14% more capital invested
Capital invested by funds: $277M → $315M (+$37.6M)
3.03% more ownership
Funds ownership: 79.2% → 82.23% (+3%)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.59M |
| 4 |
RI
RTW Investments
New York
|
+$4.16M |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$7.49M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$6.56M |
| 3 |
PA
Perceptive Advisors
New York
|
-$6.29M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$6.02M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$4.6M |
CTMX Hedge Fund Activity: Q2 2020 in Review
134 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2020, worth a combined $315M — up 14% from $277M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CTMX positions and 15 closed out — a net gain of 17 holders — while 47 added to existing stakes and 38 trimmed.
The largest buyer was Great Point Partners, adding an estimated $12.2M. The largest seller was BVF Inc, cutting an estimated $7.49M.
- 134 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2020, up from 117 in Q1 2020.
- Funds reported $315M of CytomX Therapeutics stock for Q2 2020, up 14% quarter-over-quarter.
- 32 funds opened new CytomX Therapeutics positions in Q2 2020 and 15 closed out, a net change of +17 holders.
- The largest CytomX Therapeutics buyer in Q2 2020 was Great Point Partners, an estimated $12.2M added.
- The largest CytomX Therapeutics seller in Q2 2020 was BVF Inc, an estimated $7.49M sold.
Based on aggregated 13F filings for Q2 2020.